Tim Wright – AfricaNewsAnalysis

Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch

24/01/2014 ANA 0

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for […]

Data at ECTRIMS to confirm Novartis’ Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS

25/09/2013 ANA 0

New data showing the benefits of Gilenya® (fingolimod) on patient outcomes in multiple sclerosis (MS) will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in […]

Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149)

08/09/2013 ANA 0

Novartis announced today new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 – indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in […]

Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase III psoriasis study

11/07/2013 ANA 0

Novartis announced July 8 top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel®* (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy. In addition, secukinumab […]

Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization

05/07/2013 ANA 0

The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). This makes Lucentis, specifically designed for […]